DK1152750T3 - Spontant dispergerbare N-benzoyl-staurosporin-sammensætninger - Google Patents

Spontant dispergerbare N-benzoyl-staurosporin-sammensætninger

Info

Publication number
DK1152750T3
DK1152750T3 DK00909165T DK00909165T DK1152750T3 DK 1152750 T3 DK1152750 T3 DK 1152750T3 DK 00909165 T DK00909165 T DK 00909165T DK 00909165 T DK00909165 T DK 00909165T DK 1152750 T3 DK1152750 T3 DK 1152750T3
Authority
DK
Denmark
Prior art keywords
benzoyl
spontaneously dispersible
staurosporine
compositions
staurosporine compositions
Prior art date
Application number
DK00909165T
Other languages
Danish (da)
English (en)
Inventor
Barbara Haeberlin
Graham Paul Matthews
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10847896&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1152750(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK1152750T3 publication Critical patent/DK1152750T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK00909165T 1999-02-16 2000-02-14 Spontant dispergerbare N-benzoyl-staurosporin-sammensætninger DK1152750T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9903547.9A GB9903547D0 (en) 1999-02-16 1999-02-16 Organic compounds
PCT/EP2000/001196 WO2000048571A1 (en) 1999-02-16 2000-02-14 Spontaneously dispersible n-benzoyl staurosporine compositions

Publications (1)

Publication Number Publication Date
DK1152750T3 true DK1152750T3 (da) 2009-08-24

Family

ID=10847896

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00909165T DK1152750T3 (da) 1999-02-16 2000-02-14 Spontant dispergerbare N-benzoyl-staurosporin-sammensætninger

Country Status (34)

Country Link
US (3) US20020061873A1 (enExample)
EP (1) EP1152750B1 (enExample)
JP (2) JP5057610B2 (enExample)
KR (2) KR20080064914A (enExample)
CN (1) CN100367930C (enExample)
AR (2) AR022589A1 (enExample)
AT (1) ATE430554T1 (enExample)
AU (1) AU765776B2 (enExample)
BR (1) BRPI0008228B8 (enExample)
CA (1) CA2362277C (enExample)
CL (1) CL2009001682A1 (enExample)
CZ (1) CZ303979B6 (enExample)
DE (1) DE60042151D1 (enExample)
DK (1) DK1152750T3 (enExample)
EC (1) ECSP083351A (enExample)
ES (1) ES2326783T3 (enExample)
GB (1) GB9903547D0 (enExample)
HK (1) HK1045807B (enExample)
HU (1) HUP0105364A3 (enExample)
ID (1) ID30504A (enExample)
IL (3) IL144512A0 (enExample)
MY (1) MY128362A (enExample)
NO (1) NO331232B1 (enExample)
NZ (1) NZ513529A (enExample)
PE (1) PE20001499A1 (enExample)
PL (1) PL198330B1 (enExample)
PT (1) PT1152750E (enExample)
RU (1) RU2266121C2 (enExample)
SI (1) SI1152750T1 (enExample)
SK (1) SK286967B6 (enExample)
TR (1) TR200102385T2 (enExample)
TW (1) TWI240636B (enExample)
WO (1) WO2000048571A1 (enExample)
ZA (1) ZA200106677B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7795246B2 (en) 1998-08-06 2010-09-14 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
US6200968B1 (en) * 1998-08-06 2001-03-13 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
BR0208306A (pt) * 2001-03-26 2004-03-09 Novartis Ag Composições farmacêuticas
PL392652A1 (pl) 2001-05-16 2010-12-06 Novartis Ag Kombinacja zawierająca N-{5-[4-(4-metylo-piperazyno-metylo)-benzoiloamido]-2-metylofenylo}-4-(3-pirydylo)-2-pirymidyno-aminę oraz środek chemoterapeutyczny, jej zastosowanie, kompozycja farmaceutyczna ją zawierająca oraz zestaw zawierający taką kombinację
EP1441737B1 (en) 2001-10-30 2006-08-09 Novartis AG Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
US20060115500A1 (en) * 2002-07-23 2006-06-01 Jithan Aukunuru Ophthalmic ointment composition comprising a drug, an ointment base and a solubilizing/dispersing agent
US7842791B2 (en) * 2002-12-19 2010-11-30 Nancy Jean Britten Dispersible pharmaceutical compositions
TWI324604B (en) * 2003-06-18 2010-05-11 Novartis Ag New use of staurosporine derivatives
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
GB0419159D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
GT200500310A (es) * 2004-11-19 2006-06-19 Compuestos organicos
WO2008021347A2 (en) * 2006-08-16 2008-02-21 Novartis Ag Method for making solid dispersions of highly crystalline therapeutic compounds
FR2918566B1 (fr) 2007-07-11 2009-10-09 Pierre Fabre Medicament Sa Composition pharmaceutique stable d'un sel hydrosoluble de vinflunine.
WO2009067221A2 (en) * 2007-11-20 2009-05-28 Cephalon, Inc. Microemulsion containing indolocarbazole compound and dosage forms containing the same
EP2229936B1 (en) * 2009-03-09 2015-05-06 PharmaSol GmbH Nanonized testosterone formulations for improved bioavailability
WO2011000811A2 (en) * 2009-06-30 2011-01-06 Novartis Ag Organic compounds
AU2010335654B2 (en) * 2009-12-22 2015-04-09 Leo Pharma A/S Cutaneous composition comprising vitamin D analogue and a mixture of solvent and surfactants
JO3337B1 (ar) * 2010-12-13 2019-03-13 Debiopharm Sa تركيبات صيدلية تشمل أليسبوريفير
US9387446B2 (en) * 2011-09-22 2016-07-12 Ariel-University Research And Development Company Ltd. Emulsions and methods of making emulsions
RU2742650C2 (ru) * 2015-12-09 2021-02-09 Фосфейдженикс Лимитед Фармацевтический состав
CN108601732A (zh) 2015-12-09 2018-09-28 磷肌酸有限公司 药物制剂
IL267006B2 (en) 2016-12-21 2024-11-01 Phosphagenics Ltd Process for phosphorylation of a complex alcohol with p4o10 at high temperatures, and products thereof
EP4058465A1 (en) 2019-11-14 2022-09-21 Cohbar Inc. Cxcr4 antagonist peptides

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4963367A (en) 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
US4735939A (en) * 1987-02-27 1988-04-05 The Dow Chemical Company Insecticidal activity of staurosporine
US5093330A (en) * 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
DE3824034C1 (enExample) * 1988-07-15 1989-09-14 Gustav 7290 Freudenstadt De Memminger
GB2222770B (en) * 1988-09-16 1992-07-29 Sandoz Ltd Pharmaceutical compositions containing cyclosporins
CA2108266C (en) * 1991-04-19 2003-06-03 Albert J. Owen Convertible microemulsion formulations
GB9113872D0 (en) 1991-06-27 1991-08-14 Sandoz Ag Improvements in or relating to organic compounds
PT589843E (pt) * 1992-09-25 2002-04-29 Novartis Ag Composicoes farmaceuticas contendo ciclosporinas
US6306421B1 (en) * 1992-09-25 2001-10-23 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5981568A (en) * 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
CH686761A5 (de) * 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
US5639474A (en) * 1993-07-01 1997-06-17 Hanmi Pharm. Ind., Ltd. Cyclosporin soft capsule composition
AU692506B2 (en) * 1993-11-17 1998-06-11 Ibah, Inc. Transparent liquid for encapsulated drug delivery
GB9325395D0 (en) * 1993-12-11 1994-02-16 Ciba Geigy Ag Compositions
AU1911095A (en) * 1994-02-18 1995-09-04 Cephalon, Inc. Aqueous indolocarbazole solutions
AU2565895A (en) * 1994-06-01 1995-12-21 Ciba-Geigy Ag Indolocarbazole derivatives for sensitizing multidrug-resistant cells to antitumor agents
GB2308545B (en) 1994-10-26 1999-06-02 Novartis Ag Pharmaceutical microemulsion preconcentrates
MY129435A (en) * 1994-10-26 2007-04-30 Novartis Ag Pharmaceutical microemulsion preconcentrates
EP0711556A1 (de) * 1994-11-09 1996-05-15 Ciba-Geigy Ag Intravenöse Lösungen für ein Staurosporinderivat
EP0733372A3 (de) * 1995-03-21 1998-05-20 Ciba-Geigy Ag Pharmazeutische Formulierungsgrundlage für Nanosuspensionen
AU4491697A (en) 1996-09-27 1998-04-17 Trega Biosciences, Inc. Compositions of therapeutic agents suitable for oral administration
DE19641672A1 (de) 1996-10-10 1998-04-16 Beiersdorf Ag Kosmetische oder dermatologische Zubereitungen auf der Basis von ethylenoxidfreien und propylenoxidfreien Emulgatoren zur Herstellung von Mikroemulsionsgelen
US5827522A (en) 1996-10-30 1998-10-27 Troy Corporation Microemulsion and method
NZ314060A (en) 1997-01-13 1997-08-22 Bernard Charles Sherman Pharmaceutical microemulsion preconcentrate comprising cyclosporin dissolved in a solvent system comprising hydrophobic solvent(s) and surfactant(s)
KR20040004416A (ko) * 1997-01-30 2004-01-13 노파르티스 아게 오일을 함유하지 않은 사이클로스포린 ａ 함유 제약 조성물
CA2294031E (en) 1997-07-29 2012-04-03 Pharmacia & Upjohn Company Self-emulsifying formulation for lipophilic compounds
AU728695B2 (en) 1997-07-29 2001-01-18 Boehringer Ingelheim International Gmbh Self-emulsifying formulation for lipophilic compounds
US6346511B1 (en) * 1997-09-08 2002-02-12 Panacea Biotec Limited Pharmaceutical composition comprising cyclosporin
US6979456B1 (en) * 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
GB9814527D0 (en) * 1998-07-03 1998-09-02 Cyclacel Ltd Delivery system
AR013276A1 (es) 1998-07-31 2000-12-13 Panacea Biotec Ltd Composicion de ciclosporina transparente
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions

Also Published As

Publication number Publication date
CN100367930C (zh) 2008-02-13
NO331232B1 (no) 2011-11-07
PL350556A1 (en) 2002-12-16
KR20080064914A (ko) 2008-07-09
TWI240636B (en) 2005-10-01
RU2266121C2 (ru) 2005-12-20
ES2326783T3 (es) 2009-10-20
US8722664B2 (en) 2014-05-13
CA2362277A1 (en) 2000-08-24
EP1152750A1 (en) 2001-11-14
SK11722001A3 (sk) 2001-12-03
CN1339963A (zh) 2002-03-13
JP2012111763A (ja) 2012-06-14
CA2362277C (en) 2010-03-30
IL144512A (en) 2011-03-31
HK1045807B (zh) 2008-12-05
BRPI0008228B8 (pt) 2021-05-25
MY128362A (en) 2007-01-31
GB9903547D0 (en) 1999-04-07
ZA200106677B (en) 2003-01-14
AU765776B2 (en) 2003-10-02
SI1152750T1 (sl) 2009-10-31
JP5057610B2 (ja) 2012-10-24
US20140056974A1 (en) 2014-02-27
DE60042151D1 (de) 2009-06-18
AR082579A2 (es) 2012-12-19
CL2009001682A1 (es) 2010-07-23
KR100880859B1 (ko) 2009-01-30
PL198330B1 (pl) 2008-06-30
WO2000048571A1 (en) 2000-08-24
NZ513529A (en) 2003-10-31
NO20013964D0 (no) 2001-08-15
PT1152750E (pt) 2009-08-07
ATE430554T1 (de) 2009-05-15
AU3154200A (en) 2000-09-04
CZ20012931A3 (cs) 2001-11-14
HUP0105364A3 (en) 2003-02-28
HUP0105364A2 (hu) 2002-05-29
US20020061873A1 (en) 2002-05-23
ECSP083351A (es) 2008-08-29
HK1045807A1 (zh) 2002-12-13
CZ303979B6 (cs) 2013-07-31
AR022589A1 (es) 2002-09-04
ID30504A (id) 2001-12-13
KR20010093281A (ko) 2001-10-27
IL192666A0 (en) 2009-02-11
JP2002537242A (ja) 2002-11-05
IL144512A0 (en) 2002-05-23
TR200102385T2 (tr) 2002-09-23
US20080070897A1 (en) 2008-03-20
SK286967B6 (sk) 2009-08-06
BR0008228A (pt) 2001-10-30
PE20001499A1 (es) 2001-01-12
EP1152750B1 (en) 2009-05-06
BRPI0008228B1 (pt) 2016-08-23
NO20013964L (no) 2001-10-15
US8575147B2 (en) 2013-11-05

Similar Documents

Publication Publication Date Title
DK1152750T3 (da) Spontant dispergerbare N-benzoyl-staurosporin-sammensætninger
AR023440A1 (es) Composiciones antitranspirantes
DE60000944D1 (de) Bohrlochzementzusammensetzungen
ATE321569T1 (de) Kombinierte impfstoffzusammensetzungen
DE69933200D1 (de) Kombinierte impfstoffzusammensetzungen
ATE303787T1 (de) Schergelzusammensetzungen
AR028197A1 (es) Composiciones antitranspirantes
IS6120A (is) Lyfjablanda
ID26549A (id) Komposisi-komposisi epotilon
ATE367793T1 (de) Schweisshemmende zusammensetzungen
DK1175220T3 (da) Nanopartikulære eplerenonkompositioner
AR027896A1 (es) Composiciones valdecoxib
ATE469550T1 (de) Antiparasitäre zusammensetzungen
ID29785A (id) Komposisi-komposisi sampo
DE60007731D1 (de) Schweisshemmende zusammensetzungen
DE69935172D1 (de) Imidosilan Zusammensetzungen
ATE369830T1 (de) Schweisshemmende zusammensetzungen
ATE314049T1 (de) Schweisshemmende zusammensetzungen
IS6398A (is) Lyfjablöndur
ID27889A (id) Komposisi-komposisi kopolimer polisiklik
FI990089L (fi) Maalikoostumukset
DE69943245D1 (de) Gaserzeugende zusammensetzung
DE60016836D1 (de) Resistzusammensetzung
DE60008022D1 (de) Schmutzbeständige zusammensetzungen
DE60000022D1 (de) Verbesserte teilchenförmige Zusammensetzungen